QuidelOrtho Q1 revenue slips to $693 million; adjusted EPS rises to $0.74
QuidelOrtho reported first-quarter 2025 revenue of $693 million, down from $711 million a year earlier, mainly due to lower COVID-19 and Donor Screening sales. Adjusted diluted EPS rose to $0.74 from $0.44, and GAAP net loss narrowed to $13 million from $1.71 billion, which included a prior-year goodwill impairment charge. The company maintained its full-year 2025 guidance, so shareholders see weaker sales offset by higher profitability.
Key points
- Total revenue was $693 million versus $711 million a year earlier; non-respiratory revenue was flat at $573 million.
- Adjusted diluted EPS was $0.74, compared with $0.44 in the prior-year period; adjusted EBITDA was $160 million versus $132 million.
- GAAP net loss was $13 million, compared with $1.71 billion a year earlier, which included a $1.74 billion goodwill impairment charge.
- Full-year 2025 guidance was maintained, including reported revenue of $2.60 to $2.81 billion and adjusted diluted EPS of $2.07 to $2.57.
The filing
Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.